Integrates RET testing into medullary workup

Medullary thyroid cancer is the thyroid cancer where the genetics can change the whole workup. This tumor comes from C cells, not the usual thyroid-hormone-producing cells, so the usual thyroid cancer playbook only gets you part of the way. The shift in current guidance is that diagnosis is no longer treated as just “look at the biopsy and schedule surgery.” It is an integrated workup — cytology, blood markers, imaging, and germline RET testing all move together. ### What makes this cancer different? Medullary thyroid cancer, or MTC, is rare — about 1% to 2% of thyroid cancers in the United States — but it is disproportionately important because it can spread early and because a meaningful share of cases are inherited. Roughly 25% are tied to hereditary syndromes driven by germline RET mutations, usually in MEN2. That means one patient’s diagnosis can turn into a family-risk finding very fast. ### Why isn’t biopsy alone enough? Fine-needle aspiration can suggest MTC, but it is not always clean or obvious on cytology. Ultrasound can find the nodule and suspicious lymph nodes, but ultrasound does not tell you the tumor biology. That is why current overviews keep pairing tissue findings with serum markers and genetics instead of treating the needle sample as the whole answer. ### Why do calcitonin and CEA matter so much? These tumors arise from calcitonin-producing C cells, so serum calcitonin is one of the most useful clues before and after surgery. CEA adds another marker that helps support the diagnosis and gives a baseline for follow-up. In practice, if cytology points toward MTC, clinicians want calcitonin and CEA quickly because those numbers help confirm what kind of tumor this is and how extensive it may be. ### Where does RET testing come in? RET testing is not an optional extra tacked on later. Current guidance treats germline RET testing as part of the standard evaluation for patients with confirmed or suspected MTC. The reason is simple — a case that looks sporadic can still turn out to be hereditary. If a germline RET mutation is found, first-degree relatives should be offered genetic counseling and cascade testing, because early detection can lead to preventive or earlier surgery in family members. ### Why does imaging still matter? Once MTC is on the table, clinicians need to know whether disease is confined to the thyroid or has already reached lymph nodes or distant sites. Neck ultrasound is the starting point. Cross-sectional imaging and other staging studies come in when tumor burden looks higher or lab values are markedly elevated. Basically, the workup is trying to answer two questions at once — what is this tumor, and how far has it gone? ### What does this change for pathology and cytology labs? The practical change is coordination. If an aspirate raises concern for MTC, the sample may need to support more than a routine cytology read. Labs may preserve material for ancillary studies, and the clinical team needs a fast path to serum marker testing and genetics referral. The catch is that a missed handoff here does not just delay diagnosis — it can also delay recognition of inherited risk in a whole family. ### Why is this framed more strongly now? Partly because targeted RET therapies have made genotype more clinically actionable in advanced disease. But even before treatment decisions, RET status matters for diagnosis, counseling, and family screening. So the newer framing is less about a brand-new test and more about putting genetics into the first-line workup instead of the afterthought bucket. ### Bottom line? The real update is conceptual. Medullary thyroid cancer is now worked up as a connected system, not a sequence of isolated tests. If MTC is suspected, the job is to line up cytology, calcitonin, CEA, imaging, and RET testing early — because the diagnosis can change both the surgery plan and the family tree.